Home/Pipeline/DehydraTECH-Nicotine

DehydraTECH-Nicotine

Smoking Cessation

Human ClinicalActiveNCT

Key Facts

Indication
Smoking Cessation
Phase
Human Clinical
Status
Active
Company

About Lexaria Bioscience

Lexaria Bioscience is a micro-cap biotech focused on commercializing its proprietary DehydraTECH™ drug delivery platform. The company's mission is to improve the performance of existing and new oral pharmaceuticals, particularly fat-soluble molecules, by increasing their bioavailability and onset speed. Its strategy is purely licensing-based, partnering with established pharmaceutical and consumer product companies to integrate DehydraTECH into their pipelines. Key achievements include a robust global patent portfolio, positive human clinical data across multiple drug classes, and a lean operational structure that extends its capital runway.

View full company profile

Other Smoking Cessation Drugs

DrugCompanyPhase
Nicotine Oral StripCTT PharmaPre-clinical
Smoking Cessation ProgramQnoviaPre-clinical
Platform ExpansionAmygdala NeurosciencesResearch
NFL-101NFL BiosciencesPhase 2
NFL-102NFL BiosciencesPhase 2
Varenicline TabletsIndoco RemediesApproved